Pfizer strikes $10.5 billion oncology deal with Chinese biotech

The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

Biotech

Scientist and Chinese biotech targeted by Beam in secrets suit

29 September 2026 The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.

More features

10x and Parse set to end sequencing feud after appeals court defeat

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

WATCH: Medmix global IP head on building business-focused IP teams

Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Align Technology notches another win in escalating clear aligner feud

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

More on this story

Editor's picks

Editor's picks

More features